E. Lecompte, . De-maistre-), . Département-de-pneumologie, P. Hôpital-européen-georges-pompidou, . Meyer et al., Laboratoire d'Hématologie, Département de Médecine Interne Département de Médecine Vasculaire

C. Vertuyft, L. Bouaziz, and . Becquemont, Pharmacogenetics and Hormonology and INSERM U693Récepteurs stéroïdiens, Physiopathologie endocrinienne et métabolique

. Funding, Support The study was supported by the Fondation de France, by the Fondation pour la

J. Rossouw, G. Anderson, R. Prentice, A. Lacroix, C. Kooperberg et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, Recherche Médicale (FRM) and Institut National de la Santé et de la Recherche References 1, pp.321-333, 2002.

P. Scarabin, E. Oger, and G. Plu-bureau, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, The Lancet, vol.362, issue.9382, pp.428-432, 2003.
DOI : 10.1016/S0140-6736(03)14066-4
URL : https://hal.archives-ouvertes.fr/hal-01026273

M. Canonico, E. Oger, G. Plu-bureau, J. Conard, G. Meyer et al., Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study, Circulation, vol.115, issue.7, pp.840-845, 2007.
DOI : 10.1161/CIRCULATIONAHA.106.642280
URL : https://hal.archives-ouvertes.fr/hal-00688234

D. Lignieres, B. Basdevant, A. Thomas, G. Thalabard, J. Mercier-bodard et al., Biological Effects of Estradiol-17?? in Postmenopausal Women: Oral Versus percutaneous Administration, The Journal of Clinical Endocrinology & Metabolism, vol.62, issue.3, pp.536-541, 1986.
DOI : 10.1210/jcem-62-3-536

C. Martucci and J. Fishman, P450 enzymes of estrogen metabolism, Pharmacology & Therapeutics, vol.57, issue.2-3, pp.237-257, 1993.
DOI : 10.1016/0163-7258(93)90057-K

A. Lee, M. Cai, P. Thomas, A. Conney, and B. Zhu, Characterization of the Oxidative Metabolites of 17??-Estradiol and Estrone Formed by 15 Selectively Expressed Human Cytochrome P450 Isoforms, Endocrinology, vol.144, issue.8, pp.3382-3398, 2003.
DOI : 10.1210/en.2003-0192

P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem et al., Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nature Genetics, vol.27, issue.4, pp.383-391, 2001.
DOI : 10.1038/86882

C. Sachse, J. Brockmoller, S. Bauer, and I. Roots, Functional significance of a C???A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine, British Journal of Clinical Pharmacology, vol.6, issue.4, pp.445-449, 1999.
DOI : 10.1046/j.1365-2125.1999.00898.x

M. Cornelis, A. El-sohemy, E. Kabagambe, and H. Campos, Coffee, CYP1A2 Genotype, and Risk of Myocardial Infarction, JAMA, vol.295, issue.10, pp.1135-1141, 2006.
DOI : 10.1001/jama.295.10.1135

X. Han, D. Ou-yang, P. Lu, C. Jiang, Y. Shu et al., Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2, Pharmacogenetics, vol.11, issue.5, pp.429-43520, 2001.
DOI : 10.1097/00008571-200107000-00006

C. Funck-brentano, M. Raphael, M. Lafontaine, J. Arnould, C. Verstuyft et al., Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity, Lung Cancer, vol.54, issue.1, pp.11-18, 2006.
DOI : 10.1016/j.lungcan.2006.06.016

C. Straczek, E. Oger, Y. De-jonage-canonico, M. Plu-bureau, G. Conard et al., Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration, Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration, pp.3495-3500, 2005.
DOI : 10.1161/CIRCULATIONAHA.105.565556

E. Thervet, D. Anglicheau, B. King, M. Schlageter, B. Cassinat et al., Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12, Transplantation, vol.76, issue.8, pp.1233-1235, 2003.
DOI : 10.1097/01.TP.0000090753.99170.89

F. Ng, D. Holt, and I. Macphee, Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation, Expert Opinion on Pharmacotherapy, vol.41, issue.13, pp.2045-2058, 2007.
DOI : 10.1016/S0009-9236(03)00056-0

M. Fromm, B. Schmidt, A. Pahl, J. Jacobi, and R. Schmieder, CYP3A5 genotype is associated with elevated blood pressure, Pharmacogenetics and Genomics, vol.15, issue.10, pp.737-741, 2005.
DOI : 10.1097/01.fpc.0000175599.49764.98

K. Kivisto, M. Niemi, E. Schaeffeler, K. Pitkala, R. Tilvis et al., CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients, American Journal of PharmacoGenomics, vol.5, issue.3, pp.191-195, 2005.
DOI : 10.2165/00129785-200505030-00005

W. Lieb, J. Bolbrinker, A. Doring, H. Hense, J. Erdmann et al., allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy, Clinical Science, vol.111, issue.6, pp.365-372, 2006.
DOI : 10.1042/CS20060075
URL : https://hal.archives-ouvertes.fr/hal-00479324

H. Ho, A. Pinto, S. Hall, D. Flockhart, L. Li et al., Association Between the CYP3A5 Genotype and Blood Pressure, Weinberger MH 2005 Association between the CYP3A5 genotype and blood pressure, pp.294-298
DOI : 10.1161/01.HYP.0000151361.31736.96

P. Wegman, S. Elingarami, J. Carstensen, O. Stal, B. Nordenskjold et al., Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women, Breast Cancer Research, vol.9, issue.1, pp.7-21200, 2001.
DOI : 10.1186/bcr1640

H. Kuhl, Pharmacology of estrogens and progestogens: influence of different routes of administration, Climacteric, vol.75, issue.19, pp.3-63, 2005.
DOI : 10.1016/S0140-6736(99)80017-8

M. Shou, K. Korzekwa, E. Brooks, K. Krausz, F. Gonzalez et al., Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone, Carcinogenesis, vol.18, issue.1, pp.207-214, 1997.
DOI : 10.1093/carcin/18.1.207

Y. Tsuchiya, M. Nakajima, and T. Yokoi, Cytochrome P450-mediated metabolism of estrogens and its regulation in human, Cancer Letters, vol.227, issue.2, pp.115-124, 2005.
DOI : 10.1016/j.canlet.2004.10.007

A. Cribb, M. Knight, D. Dryer, J. Guernsey, K. Hender et al., Role of Polymorphic Human Cytochrome P450 Enzymes in Estrone Oxidation, Cancer Epidemiology Biomarkers & Prevention, vol.15, issue.3, pp.551-558, 2006.
DOI : 10.1158/1055-9965.EPI-05-0801

J. Liehr, Is estradiol a genotoxic mutagenic carcinogen?, Endocrine reviews, vol.21, issue.16, pp.40-5420, 2000.

G. Swaneck and J. Fishman, Covalent binding of the endogenous estrogen 16 alpha-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization., Proceedings of the National Academy of Sciences, vol.85, issue.21, pp.7831-7835, 1988.
DOI : 10.1073/pnas.85.21.7831

Z. Huang, F. Guengerich, and L. Kaminsky, 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5, Carcinogenesis, vol.19, issue.5, pp.867-872, 1998.
DOI : 10.1093/carcin/19.5.867

B. Zhu and A. Conney, Functional role of estrogen metabolism in target cells: review and perspectives, Carcinogenesis, vol.19, issue.1, pp.1-27, 1998.
DOI : 10.1093/carcin/19.1.1

F. Rosendaal, F. Helmerhorst, and J. Vandenbroucke, Female Hormones and Thrombosis, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.22, issue.2, pp.201-210, 2002.
DOI : 10.1161/hq0202.102318

T. Simon, B. Yon-de-jonage-canonico, M. Oger, E. Wahl, D. Conard et al., Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism, Journal of Thrombosis and Haemostasis, vol.85, issue.1, pp.71-7620, 2006.
DOI : 10.1046/j.1365-2265.1997.2601068.x
URL : https://hal.archives-ouvertes.fr/hal-00688975